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Abstract: Even after a century, heparin is still the most effective anticoagulant available with few
side effects. The poor oral absorption of heparins triggered the search for strategies to achieve oral
bioavailability since this route has evident advantages over parenteral administration. Several
approaches emerged, such as conjugation of heparins with bile acids and lipids, formulation
with penetration enhancers, and encapsulation of heparins in micro and nanoparticles. Some of
these strategies appear to have potential as good delivery systems to overcome heparin’s low oral
bioavailability. Nevertheless, none have reached the market yet. Overall, this review aims to provide
insights regarding the oral bioavailability of heparin.
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1. Introduction
Heparin has been one of the most effective and widely used drugs of the past century. Discovery
of heparin dates back to 1916, when isolated blood fractions that were able to clot blood were identified
by Jay McLean, a second-year medical student working under the direction of William Howell [1].
Chemically, heparin is a mixture of highly sulfated glycosaminoglycans with molecular weight
around 15 kDa. The presence of sulfate and carboxylic acid groups in the structure of heparin makes
it one of the most negatively charged biological macromolecules in nature [2–4]. In physiological
conditions, ionization of sulfate and carboxylic acid groups takes place, which attracts positively
charged counter ions, more commonly sodium, to form a heparin salt.
Low molecular weight heparins (LMWHs), such as unfractioned heparin (UFH), are also mixtures
of glycosaminoglycans but with an average molecular weight of about 5 kDa [5]. LMWHs derive
from UFH by chemical or enzymatic depolymerization and have a more predictable pharmacokinetic
profile [6] and a slightly different mechanism of action.
A unique pentasaccharide sequence present in both UFH and LMHWs is essential for their
anticoagulant activity. UFH binds to antithrombin III (ATIII) that undergoes a conformational change
and becomes activated as an inhibitor of thrombin and factor Xa (FXa) while LMWHs are shorter and
show limited inhibition of thrombin [5]. Because the bioavailability of subcutaneous UFH is lower than
that of intravenous UFH, UFH is preferably administered intravenously to avoid the administration
of large doses of subcutaneous UFH [7]. Bioavailability of subcutaneous LMWHs is higher than that
of subcutaneous UFH, so LMWHs are administered subcutaneously [5]. However, none exhibit oral
bioavailability due to their highly negative charge, large molecular weight [8], and rapid metabolism
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in gastrointestinal (GI) tract (Figure 1) [9]. The rapid metabolism in the GI tract is mainly due to low
stability at low pH [10] and enzymatic degradation by intestinal microflora [11,12]. Additionally, after
GI absorption heparins undergo high first pass metabolism by heparinase in the liver [13].
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Figure 1. Structural features of heparins that limit their oral bioavailability. UFH—Unfractioned heparin. 
Parenteral administration of heparins is a costly and invasive method that leads to low patient 
adherence. On the other hand, vitamin K antagonists (VKA), orally active anticoagulants, suffer 
from a number of limitations, namely high food and drug interactions, long onset/offset of action, 
and need of regular monitoring by blood tests. New oral anticoagulants were recently introduced in 
the market that overcome some of those VKA limitations, namely dabigatran (direct thrombin 
inhibitor), rivaroxaban, apixaban, and edoxaban (FXa inhibitors), but there are some hesitations 
about their wide use in the treatment of thromboembolic diseases, namely the absence of an antidote 
and extensive drug interaction with P-glycoprotein (P-gp) substrates [14]. In general, heparins have 
several advantages over VKA and new oral anticoagulants (Figure 2) which makes them the most 
effective anticoagulants available. Furthermore, all these orally active anticoagulants lack the 
polypharmacological actions of heparins which are thought to be involved beyond the coagulation 
cascade [15], like antimetastatic [16] and anti-inflammatory activities [17]. 
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Parenteral administration of heparins is a costly and invasive method that leads to low patient
adherence. On the other hand, vitamin K antagonists (VKA), orally active anticoagulants, suffer from
a number of limitations, namely high food and drug interactions, long onset/offset of action, and
need of regular monitoring by blood tests. New oral anticoagulants were recently introduced in the
market that overcome some of those VKA limitations, namely dabigatran (direct thrombin inhibitor),
rivaroxaban, apixaban, and edoxaban (FXa inhibitors), but there are some hesitations about their wide
use in the treatment of thromboembolic diseases, namely the absence of an antidote and extensive drug
interaction with P-glycoprotein (P-gp) substrates [14]. In general, heparins have several advantages
over VKA and new oral anticoagulants (Figure 2) which makes them the most effective anticoagulants
available. Furthermore, all these orally active anticoagulants lack the polypharmacological actions of
heparins which are thought to be involved beyond the coagulation cascade [15], like antimetastatic [16]
and anti-inflammatory activities [17].
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The development of a non-invasive delivery of heparin is undoubtedly an unmet clinical need. 
Therefore, several strategies that promote the absorption of heparins in GI tract have been 
investigated in the last decades. 
Although the oral route is by far the most desirable, it is important to emphasize that there also 
have been attempts to achieve bioavailability of heparins through other routes, such as nasal [18], 
pulmonary [19], and transdermal [20]. 
This review focus on (physico-)chemical-biological and technological strategies that are 
expected to improve oral bioavailability of heparins, namely the increase of lipophilicity, target 
receptor-mediated endocytosis, modifications of the tight junctions, enhancement of cell 
permeabilization, and protection against acidic pH of the stomach and GI metabolism. 
2. Heparin Conjugates
Following a drug conjugate strategy, heparins have been covalently bond to other molecules in 
order to achieve oral bioavailability in one of two ways: increasing lipophilicity and permeability or 
enabling absorption via transporter proteins [21]. 
Lipids and deoxycholic acid (DOCA) (Figure 3) have been proven to be suitable choices for 
conjugation with heparins [22–34]. As they are naturally occurring substances, the administration of 
these conjugates may involve few toxic effects [32]. Conjugates of heparin with palmitic acid, lauric 
acid, and cholesterol (Figure 3) were reported [32]. Absorption of these heparin-lipids conjugates 
increased in rats, probably due to their higher lipophilicity. Nevertheless, heparin-cholesterol and 
heparin-fatty acids conjugates showed lower effect in clotting times than heparin-DOCA conjugates 
[32]. DOCA is a secondary bile acid produced from cholesterol and one of its functions is to 
stimulate intestinal lipids absorption [35]. 
DOCA is absorbed in the intestinal membrane through apical sodium bile acid transporters and 
this mechanism of absorption was also hypothesized to increase the transcellular absorption of 
heparins [22]. Numerous studies have proven that heparins-DOCA conjugates increased oral 
bioavailability of heparins by increasing their intestinal absorption (Figure 4A–C) [23,24,26,27,32]. 
DOCA was conjugated with heparins using different synthetic approaches, all of them involving the 
formation of one amide bond (Figure 4A–D). Some conjugates involved the carboxylic groups of 
heparin to conjugate with DOCA (Figure 4A,B) and others the amine groups (Figure 4C). Lee et al. 
carried out histological examination of GI tissue membrane after oral administration of 
heparin-DOCA and showed no damage on microvilli and cell layer [27,31,32]. These results proved 
that the increased absorption of heparins conjugates was not caused by the disruption of the GI 
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Figure 2. Advantages of heparins over vitamin K antagonists (VKA) and new oral anticoagulants
(NOACs) drugs.
The development of a non-invasive delivery of heparin is undoubtedly an unmet clinical need.
Therefore, several strategies that promote the absorption of heparins in GI tract have been investigated
in the last decades.
Although the oral route is by far the most desirable, it is important to emphasize that there also
have been attempts to achieve bioavailability of heparins through other routes, such as nasal [18],
pulmonary [19], and transdermal [20].
This review focus on (physico-)chemical-biological and technological strategies that are
expected to i prove oral bioavailability of heparins, namely the increase of lipophilicity,
target receptor-mediated endocytosis, modifications of the tight junctions, enhancement of cell
permeabilization, and protection against acidic pH of the stomach and GI metabolism.
2. Heparin Conjugates
Following a drug conjugate strategy, heparins have been covalently bond to other molecules in
order to achieve oral bioavailability in one of two ways: increasing lipophilicity and permeability or
enabling absorption via transporter proteins [21].
Lipids and deoxycholic acid (DOCA) (Figure 3) have been proven to be suitable choices for
conjugation with heparins [22–34]. As they are naturally occurring substances, the administration of
these conjugates may involve few toxic effects [32]. Conjugates of heparin with palmitic acid, lauric acid,
and cholesterol (Figure 3) were reported [32]. Absorption of these heparin-lipids conjugates increased
in rats, probably due to their higher lipophilicity. Nevertheless, heparin-cholesterol and heparin-fatty
acids conjugates showed lower effect in clotting times than heparin-DOCA conjugates [32]. DOCA is a
secondary bile acid produced from cholesterol and one of its functions is to stimulate intestinal lipids
absorption [35].
DOCA is absorbed in the intestinal membrane through apical sodium bile acid transporters
and this mechanism of absorption was also hypothesized to increase the transcellular absorption
of heparins [22]. Numerous studies have proven that heparins-DOCA conjugates increased oral
bioavailability of heparins by increasing their intestinal absorption (Figure 4A–C) [23,24,26,27,32].
DOCA was conjugated with heparins using different synthetic approaches, all of them involving
the formation of one amide bond (Figure 4A–D). Some conjugates involved the carboxylic groups of
heparin to conjugate with DOCA (Figure 4A,B) and others the amine groups (Figure 4C). Lee et al.
carried out histological examination of GI tissue membrane after oral administration of heparin-DOCA
and showed no damage on microvilli and cell layer [27,31,32]. These results proved that the increased
absorption of heparins conjugates was not caused by the disruption of the GI epithelium.
Pharmaceuticals 2016, 9, 37 4 of 16Pharmaceuticals 2016, 9, 37 4 of 16 
 
 
Figure 3. Chemical structure of deoxycholic acid (DOCA), fatty acids, and cholesterol. 
One problem associated with the use of DOCA is that the conjugate with heparins forms 
micelles in water and DOCA is located within the core of micelles. As a consequence, lower 
interaction of DOCA with apical sodium bile acid transporters occurs, limiting the absorption of the 
conjugate. Thus, the bioavailability of heparin-DOCA conjugates was improved through the 
formulation with dimethylsulfoxide (DMSO) as a solubilizer [22,28,30,31]. DMSO is known to 
interfere with lipid membranes [36]. The absorption of heparin-DOCA with DMSO was three times 
higher compared with heparin-DOCA conjugate alone. Later, Kim et al. developed a tricaprylin 
microemulsion to dissolve heparin-DOCA conjugate [34]. Microemulsions are thermodynamically 
stable, liquid mixtures of oil, water, surfactant and co-surfactant that are used in pharmaceutical 
science to improve the solubility of drugs (amphiphilic or lipophilic). Tricaprylin is a medium-chain 
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[41,42] activities. These studies reported for the first time the antitumor effect of an orally active 
heparin and confirmed that it inhibits tumor angiogenesis. The co-administration of LMWH-DOCA 
conjugate and docetaxel, a drug widely used in the treatment of several human cancers, showed a 
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in wat r a d DOCA is located within the core of micelles. As a cons quence, lower interacti n of
DOCA with apical sodium bile aci transporters occurs, limiting the absorption of the c jugate.
Thus, the bioavailability f hep rin-DOCA conjugates was improved through the formulation with
dimethylsulfoxide (DMSO) as a solubilizer [22,28,30,31]. DMSO is known to interfere with lipid
memb anes [36]. The absorption of heparin-DOCA with DMSO was three times higher compared
wit heparin-DOCA conjugate alone. Later, Kim et al. dev loped a tricaprylin microemulsion to
dissolve heparin-DOCA conjugate [34]. Microemulsions are therm dynamically stable, liquid mixtures
of oil, water, surfactant and co-surfactant that are used in pharmaceutical science to improve the
olubility of drugs (amphiphilic or lipophilic). Tricaprylin is a medium-chain triglyceride marketed as
a medical food for he clinical ietary management of Alzh imer’s disease. Heparin-DOCA conjugate
in w ter was mixed with tricaprylin, polyoxyethylene 20 sorbitan monooleate (Tween 80) and i
laurate Span 20). Heparin-DOCA conjugate was dissolved in a microemulsion with tricaprylic
and the absorption efficiency of the heparin conjugat was increas d indicating that solubilization of
hepari -DOCA conjugate is important for the absorption in the intesti e.
A recent study r ported the absorption of a heparin-tetrameric DOCA conjugate (Figure 4D) with
a remarkable systemic anticoagulant activ ty and high o al bioavailability of 33.5% and 19.9% in rats
and monkeys, respectiv ly [37]. This study showed functional transform tion of apical sodium bile
acid transporters upon interaction with tetrameric DOCA d rivative, which led to recept r-mediated
en ocytos s [38].
C nventional anticancer drugs are toxic, and research is focus in the development of more specific
drugs that target only molecular abnormalities specific to c ncer cells. The ben fits of heparin in cancer
are both ependent and independent from its anticoagulant activ t es [39]. A LMWH-DOCA conjugate
(Figu e 4A) was also t sted for antim tastatic [40] and antiangiogenic [41,42] activities. These studies
reported for the first time the antitumor effect of an orally active heparin nd confirmed that it inhibits
tumor ang ogenesis. The co-administration f LMWH-DOCA conjugate and docetaxel, a drug widely
used in the treatment of several human cancers, sh wed a hig r tumor growth i hibition compared
to LMWH-DOCA conjug te or docetaxel alone [42]. Considering that DOCA has low solubility in
water, LMWHs were conjugated with tau ocholic acid and docetaxel [43,44]. Oral bio vail bility and
Pharmaceuticals 2016, 9, 37 5 of 16
synergistic effects of heparin and docetaxel were observed in this conjugate. Recently, a conjugate of
LMWH with taurocholic acid and tetrameric DOCA was prepared and an increased oral bioavailability
and promising angiogenesis inhibition were observed [45]. The same conjugate was co-administered
with deoxycholyl-L-lysyl-methylester and an increased oral bioavailability was also observed [46].
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Figure 4. Structure of different heparins-D j t . ( ) eparin-DOCA conjugate in which
both carboxylic groups arin and DOCA were conjugated through a linker [22–24,30,31,33];
(B) Heparin-DOCA conjugate in which a carboxylic group of heparin and a hydroxyl group of
DOCA were conjugated through a linker [29]; (C) Heparin-DOCA conjugate in which an amine
grou of heparin and a carboxylic group of DOCA were conjugated without a linker [ 5–28,32];
(D) Heparin-tetrameric DOCA conjugate [37].
However, there are a number of bile acids available, with different affinities to apical sodium
bile acid transporters. In a study considering the effect of different bile acids on the uptake of
taurocholate assay [47], chenodeoxycholic acid was the most efficient, followed by DOCA, cholic acid,
ursodeoxycholic acid, and litocholic acid. Therefore, it would be interesting to study the conjugation
of heparin with other bile acids, namely with chenodeoxycholic acid.
Conjugation with several bile acids, including DOCA, was successfully performed to improve
oral bioavailability of other drugs, namely acyclovir [47] and insulin [48] but none have yet entered
clinical trials. Consequently, c njugation of heparins with bile acids seems a valuable strategy to
improve oral bioavailability of hepari s. However, this str tegy will not protect hepar ns from
degr d tion in the stoma h, intestine, and liver. On the othe hand, ther are some studies indicating
that an incre sed colonic exposure to bile acids could play a r le in the development of ancer, since
higher fec l concentrations of bile acids were found in populations with a high in idenc of colorectal
cancer [49–51], and the levels of exposure to bile acids must be considered in the development of
heparin-bile acids conjugates.
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3. Co-Administration with Penetration Enhancers
In this section, penetration enhancers that have already been used to improve UFH and LMWHs
absorption is revised. The weak association between penetration enhancers and drugs allows the
spontaneous release of the drug into the circulation [52]. However, in contrast to drug conjugate
strategy, some dissociation before absorption cannot be excluded.
Penetration enhancers improve absorption of drugs in the GI tract either through paracellular
absorption, by opening the tight junctions between adjacent cells, or through transcellular absorption,
by increasing the lipophilic properties of the drug (Figure 5) [21,53]. Many of the penetration
enhancers that act through paracellular absorption are described as causing cytotoxicity or membrane
damage [54].
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(ardeparin) was increased in the presence of L-arginine in Caco-2 cells [55]. In vivo studies in rats 
showed that absorption of ardeparin in the presence of L-arginine is higher in the colon and 
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Figure 5. Chemical structure of penetration enhancers that increase oral bioavailability of
heparins. MCC—Mono-N-carboxymethyl chitosan; SNOCC: N,O-Carboxymethyl chitosan; PCP-Cys:
Polycarbophil-cystein; D C N,N-Di ethyl chitosan; S AD Sodiu N-[10-(2-hydroxybenzoyl)
a ino decanoate; SNAC: Sodiu N-(8-[2-hydroxybenzoyl] amino) caprylate.
3.1. Paracellular bsorption
L- rginine (Figure 5), a nonessential amino acid, is the principal physiological precursor of nitric
oxide and plays a versatile role in the GI tract physiology. Intestinal absorption of a LMWH (ardeparin)
was increased in the presence of L-arginine in Caco-2 cells [55]. In vivo studies in rats showed that
absorption of ardeparin in the presence of L-arginine is higher in the colon and jejunum, and for 250 mg
of L-arginine it was observed an increased anti-FXa activity compared with ardeparin alone. A sodium
bicarbonate solution was ad inistered with the LMWH/L-arginine formulation to increase the acidic
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pH of the stomach and to avoid degradation. Anti-FXa activity was used for estimating plasma levels
of LMWH and a significant increase in plasma anti-FXa levels within 90 min to 0.26 IU/mL was
observed after administration of ardeparin/L-arginine formulation (~2 fold compared with the control,
0.13 IU/mL). The effect of several concentrations of L-arginine on cell viability was investigated
through mitochondrial dehydrogenase activity and there was no significant variation compared to the
negative control [55].
18β-Glycyrrhetinic acid (GA, Figure 5) is a pentacyclic triterpenoid amyrin derivative obtained
from the hydrolysis of glycyrrhizic acid, naturally present in the roots of the plant Glycyrrhiza glabra.
GA was tested as a penetration enhancer in order to increase the intestinal absorption of LMWHs [56].
A sodium bicarbonate solution was also administered with the LMWH/GA formulation. Absorption of
LMWHs was increased both in vitro and in vivo after co-administration with GA. Anti-FXa activity was
used for estimating plasma levels of LMWH and a significant increase in plasma anti-FXa levels within
4 h to 0.28 IU/mL was observed after administration of GA (50 µg/kg) with ardeparin (1200 IU/kg).
After exposure to GA, no significant toxicity was found in Caco-2 cells monolayers, at relatively
low concentrations. The authors hypothesised that GA acts by increasing paracellular absorption
of LMWHs [57]. This study was conducted by Hisamitsu Pharmaceutical Co., Inc. (Saga Prefecture,
Japan); however, at the moment, GA seems to be applied only on transdermal formulations with
pain relief drugs [58]. Recently, anticoagulant properties through uncompetitive inhibition of FXa
were described for GA [59]. Therefore, co-administration of heparin with GA seems an interesting
strategy that could increase both intestinal absorption and FXa inhibition. However, higher bleeding
risk should be considered.
Mucoadhesive polymers increase the residence and the contact times of the drug with mucous
membranes leading to a longer-lasting therapeutic effect [60]. These polymers are not absorbed in
the GI tract due to their high molecular weight. Three mucoadhesive polymers, chitosan derivatives,
poly(acrylates) and thiolated polymers, were described to increase the absorption of heparins in GI
tract [61–66].
Chitosan is a polysaccharide with mucoadhesive properties comprising glucosamine and
N-acetylglucosamine subunits [54]. In vitro studies have shown that chitosan opens epithelial tight
junctions in a concentration- and pH-dependent way [54]. However, chitosan was incompatible with
LMWHs [67] and chitosan derivatives were prepared [61,62]. Mono-N-carboxymethyl chitosan (MCC,
Figure 5), a polyampholyte chitosan derivative was shown to increase in vitro paracellular absorption
of LMWHs in Caco-2 cell monolayers [61]. The in vivo intestinal absorption of LMWHs was also
increased with MCC in rats. Anti-FXa activity was used for estimating plasma levels of LMWH and
therapeutic LMWH levels (0.3–0.7 anti-FXa U/mL) were reached 3 h after administration with MCC.
A sulfonate derivative of N,O-carboxymethyl chitosan (SNOCC, Figure 5) increased the permeation
and absorption of LMWHs both in vitro (Caco-2 cell monolayers) and in vivo (rats) after intraduodenal
administration [62]. The absorption of reviparin was assessed by measuring the anti-FXa plasma levels
and an increase in plasma anti-FXa levels to 0.4 anti-Xa U/mL was observed after administration of
SNOCC at 3% (w/v) with reviparin. Recently, another chitosan derivative, N,N-dimethyl chitosan
(DMC, Figure 5), was used to form a polyelectrolyte complex with UFH [63]. In vitro release studies
showed that heparin is released from the complex which indicates that DMC could be used to increase
the oral bioavailability of heparin. Moreover, DMC was able to efficiently protect heparin in simulated
gastric fluid in which heparin is degraded. Chitosan oligomers (Figure 5) are obtained through
complete deacetylation of chitosan and according to the number of sugar units in their structure
they are dimer, tetramer, or hexamer. In contrast to chitosan, which has poor solubility in water at
physiological pH, these chitosan oligomers are water-soluble and have relative low molecular weight.
Absorption of LMWHs from the small intestine of rats was greatly increased in the presence of an
optimal concentration of 0.5% (w/v) of chitosan hexamer, and the absorption of LMWH was dependent
on the concentration of hexamer [64]. Biological markers such as protein and lactate dehydrogenase
released from intestinal epithelial cells were measured to assess the toxicity of chitosan hexamers after
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intestinal administration and revealed that chitosan oligomers did not induced remarkable membrane
damage to the intestine over the concentration range tested and therefore these compounds could be
used as penetration enhancers with possibly few toxic effects [64].
The co-administration of LMWHs with poly(acrylate) derivative Carbopol 934P, which interferes
with the intercellular junctions, was investigated. LMWH intestinal absorption was achieved with
enhanced anti-FXa levels after administration of 10,800 anti-Xa U/kg LMWH with 1% (w/v) Carbopol
934P and the effect was sustained for 6 h [66].
Thiolated polymers or thiomers improve mucoadhesion properties and permeation enhancing
properties due to the thiol groups [65]. The presence of thiol groups offers the advantage of forming
disulfide bonds between these novel polymers and the mucus gel layer, mimicking the natural
mechanism of secreted mucus glycoproteins, which are also covalently anchored in the mucus layer
by the formation of disulfide bonds [60]. Polycarbophil-cystein (PCP-Cys, Figure 5) is a thiomer that
was found to increase the absorption of LMWHs achieving anticoagulant levels when formulated
with glutathione (GSH) [65,68]. The oral administration of a LMWH with PCP-Cys/GSH resulted in
a significantly increase of LMWH absorption compared with control tablets comprising unmodified
PCP or with an orally given aqueous LMWH solution, with an absolute bioavailability of ~20% [65].
Labrasol is a well-defined mixture of glycerides and fatty acids esters which was described
to enhance the intestinal absorption of LMWHs [69,70]. The anti-FXa plasma levels obtained after
administration of a formulation containing 200 IU/kg of LMWH and 50.0 mg/kg of labrasol was
0.50 IU/mL, which was considered adequate to exert anticoagulant activity in plasma. Significant
absorption of LMWHs occurred in jejunum compared with duodenum and ileum. Intestinal membrane
permeability changes induced by labrasol were transient and reversible. Later, LMWHs were dispersed
with labrasol and the mixture was solidified with three different adsorbents (microporous calcium
silicate, magnesium aluminometa silicate, and silicon dioxide) [71]. In a dissolution study developed
in vitro, silicon dioxide system showed the fastest release rate of LMWHs among the used emulsifiers
but in in vivo studies, microporous calcium silicate system showed the highest plasma anti-FXa
activity (Cmax = 0.42˘ 0.01 IU/mL) [71]. However, the mechanism by which labrasol increases LMWH
intestinal absorption has not been elucidated, though it is believed to be a combination of increased
solubility and enhanced permeability.
3.2. Transcellular Absorption
SodiumN-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) and sodiumN-[10-(2-hydroxybenzoyl)
amino] decanoate) (SNAD) (Figure 5) are non α-aminoacids that interact non-covalently with
heparin, neutralizing its negative ionic charge to render it more lipophilic, and allowing transcellular
absorption [72]. Once the complex crosses the membrane, SNAC dissociates from the therapeutic
agent [52,72]. SNAC increased the absorption of heparin through the GI tract in therapeutic doses [73].
Oral heparin/SNAC entered clinical trials and showed good results in healthy volunteers and in
patients undergoing elective total hip arthroplasty [74]. Oral LMWHs/SNAD also prevented deep
venous thrombosis [75]. These studies demonstrated for the first time that heparins can be effectively
orally delivered into the bloodstream in patients [76].
A randomized, double-blind, controlled study performed in humans to study the safety and the
effect of heparin/SNAC in anticoagulation showed that heparin/SNAC increased the coagulation
parameters (APTT, anti-FIIa and FXa, and tissue factor pathway inhibitor) and, that neither heparin or
SNAC alone changed these parameters [77]. A major limitation seems to be heparin high first pass
metabolism by heparinase in the liver after GI absorption. In a phase I clinical trial to characterize the
pharmacokinetic/pharmacodynamic profile of heparin administered orally with SNAC to healthy
volunteers, a higher dose of oral heparin/SNAC (75,000 IU) was necessary to achieve an anticoagulant
effect similar to parenteral administration (10,000 IU) [78]. For both anti-FXa and IIa activity, oral
heparin/SNAC formulation showed higher half-life time compared to intravenous injection of heparin
sodium (0.666 U/mL vs. 0.0841 U/mL). Anti-FXa achieved at peak with oral heparin was 0.547 U/mL,
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lower than with parenteral administration for both anti-FXa and IIa activities. Area under the curve
was also lower for oral heparin/SNAC than parenteral administration, for both anti-FXa and IIa
activities. However, in Phase III clinical trial oral formulation of heparin/SNAC did not show superior
efficacy compared to enoxaparin in patients that undergone total hip replacement [79]. Additionally,
unexpected low compliance was observed due to the bad taste.
Polycationic lipophilic-core dendrons (Figure 5) have been shown to enhance absorption of
LMWHs in rats [80]. After administration of LMWH (7500 IU/kg) with a polycationic lipophilic-core
dendron (7 mol equivalents) a significantly increase in Cmax was observed. These structures establish
lipophilic ion-pairs with the polyanionic LMWHs making them more hydrophobic. This ion-pair
model of absorption assumes that the dendrons are absorbed as a complex with LMWHs. However,
poor aqueous solubility of the complex dendron-LMWHs limited their absorption. Through lipophilic
ion pairing, Lee et al. designed a DOCA derivative, deoxycholylethylamine (DOCA-NH2) (Figure 5),
to complex with LMWHs [81]. The complex was dissolved in propylene glycol and administered in
rats by oral gavage. Physical association of DOCA-NH2 with LMWHs turned the later more lipophilic
and in vivo experiments indicated that DOCA-NH2 significantly affected the oral absorption of the
LMWHs, and at a molar ratio of 1:5 the oral absorption of LMWHs was high. An anti-FXa value of
0.83 ˘ 0.11 IU/mL was observed after oral administration of a 50 mg/kg dose of LMWH/DOCA-NH2.
Nevertheless, the complex LMWHs/DOCA-NH2 showed reduced solubility due to its size and
propylene glycol had to be used as solubilizer. The oral absorption of LMWHs/DOCA-NH2 complex
was higher than of LMWHs/DOCA complex. The mechanism by which LMWHs absorption is
improved is not clear and may be related to bile acids transporters or passive absorption. However,
toxicological studies were not performed.
A number of penetration enhancers were shown to improve oral availability of heparins. In this
strategy, chemical structure of heparins is preserved [82] and once the complex crosses the membrane,
penetration enhancers dissociate spontaneously from the therapeutic agent [52]. However, systemic
toxic side effects of these compounds cannot be excluded [83]. Consequently, mucoadhesive polymers,
which are not absorbed in the GI tract due to its high molecular weight, seem more valuable compared
to other penetration enhancers. In general, poor solubility of complexes formed with heparins,
local and systemic toxic effects, and the fact that heparins’ degradation is not avoided, are the main
drawbacks of this strategy.
4. Micro and Nanoparticles
Micro and nanoparticles have received considerable interest in recent years due to their ability to
control the pattern of drugs’ release and due to their good pharmacokinetics.
Both polymeric micro and nanoparticles have been used to improve oral absorption of
heparins [84–90]. Additionally, due to their unique physical and biological properties [91],
nanoparticles protect heparins from pH and enzymatic degradation and are able to completely avoid
the first pass metabolism by the liver.
Biodegradable polymers (poly-ε-caprolactone and poly-D,L-lactic-co-glycolic acid) and
non-biodegradable polymers (Euparin dragit® RS and RL) were used to prepare heparin-loaded
nanoparticles [84,86,88,90]. Anticoagulant activity was maintained, but only in vitro studies were
performed. These polymers were also used to prepare microparticles to encapsulate heparin [85]. Initial
in vitro tests showed satisfactory encapsulation efficiency and controlled drug release with retention
of the anticoagulant activity [90]. Further in vivo studies in rabbits showed absorption of heparin
after oral administration [88]. The mechanism involved in the enhancement of oral bioavailability of
heparin loaded polymeric nanoparticles was hypothesized to be through mucoadhesion: first there is
an electrostatic interaction between nanoparticles and mucus, and after that heparin on the particle
surface is released and replaced by mucin [92].
Microparticles obtained through complex coacervation of an optimized LMWH/acacia gum
mixture with either gelatin A or B led to an increase of the oral bioavailability of tinzaparin [93].
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Gelatin B microparticles showed higher oral bioavailability compared with gelatin A which was
negligible. In vitro drug release occurred at physiological pH (pH 7.4).
Later, LMWH-loaded nanoparticles were prepared using polyester and polycationic
polymethacrylate [84]. Oral absorption of this LMWH was improved and its anticoagulant effect was
prolonged for up to 8 h.
Chen et al. prepared a nanoparticle system shelled with low molecular weight chitosan for oral
delivery of heparin [94] that releases heparin at physiological pH. Chitosan and heparin were able to
form polyelectrolyte complexes via electrostatic interaction at low pH, resulting in a matrix structure
with a spherical shape with average diameters in the nano scale. A significant anticoagulant activity in
plasma was observed after oral administration in rats. Intestinal absorption of heparin was significantly
enhanced with a total bioavailability of 20.5%. A biodistribution study was performed and it suggested
that the absorption of chitosan into the systemic circulation is minimal. Chitosan nanoparticles have
been coated with an anionic polysaccharide alginate and tested as an efficient drug delivery system
to achieve intestinal absorption of a LMWH (enoxaparin) [95]. Anionic polysaccharide alginate was
used to overcome the problems of low solubility of chitosan at physiological pH. Alginate-coated
chitosan nanoparticles loaded with enoxaparin released only 2% of the LMWH in simulated gastric
fluid (pH 1.2) with faster release rate in simulated intestinal fluid conditions leading to the release of
more than 60% of the LMWH. In vitro permeation studies showed that more than 75% of enoxaparin
was transferred across the intestinal epithelium after 90 min. The in vivo pharmacokinetic studies
showed that the alginate-coated chitosan nanoparticles significantly enhanced the oral bioavailability
of enoxaparin compared with enoxaparin solution. LMWHs loaded N-trimethyl chitosan (TMC)
nanoparticles were developed by Paliwal et al. to achieve oral bioavailability of LMWHs through
mucoadhesive properties of chitosan derivatives [96]. These nanoparticles increased 2.4 times the
bioavailability of LMWHs in comparison to LMWH solution.
In the literature, there is a combination of strategies through the encapsulation of heparin-lipid
and heparin-DOCA conjugates in solid lipid nanoparticles [25]. Solid lipid nanoparticles consist of
biodegradable physiological lipids or lipidic substances and stabilizers which are generally recognized
as safe [97]. Encapsulation of this conjugate into solid lipid nanoparticles of phosphatidylcholine
significantly improved the bioavailability of LMWHs after oral route administration with insignificant
toxicity to different GI tissues. Histological examination of GI tract tissues after one hour of oral
administration of heparin-lipid conjugate loaded solid lipid nanoparticles was performed and toxicity
was not found in any part of the GI epithelium [25].
More recently, LMWHs were encapsulated in particles with polyaminomethacrylates (Eudragit®
RL or RS) using polyethylene glycol derivatives as solvents [98]. The use of short chain polyethylene
glycol derivatives is a possible advantage due to their low toxicity when compared with other solvents
and achieved nearly a complete drug release in vitro.
One advantage of micro and nanoparticles is that they protect heparins from degradation and at
the same time promote heparin absorption in the GI tract. Nevertheless, this approach has drawbacks
related to the delay created in drug absorption and the lack of control retained over absorption time as
a result of the variability in intestinal motility and gastric emptying. Toxicity also has to be considered,
since polymeric materials modify tight junctions and could lead to the absorption of endotoxins and
other potentially toxic compounds [99].
5. Conclusions
Heparin has unique properties that are not achieved with new oral anticoagulants. The
development of an orally active heparin will avoid the inconvenience of parenteral administration.
In the last few years, several strategies have been attempted in order to overcome heparin’s poor
bioavailability: conjugation with lipophilic molecules, co-administration with penetration enhancers,
and micro and nanoparticles. While the chemical structure of heparins is preserved with penetration
enhancers and the release from the therapeutic agent occurs spontaneously, dissociation before
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absorption is avoided by chemical conjugation. With both strategies, heparin’s degradation is
not circumvented. In contrast, micro and nanoparticles protect heparins from pH and enzymatic
degradation and are able to avoid the first pass metabolism. Efficient absorption with minimal toxicity
has been the major concern. In fact, some of these strategies may modified tight junctions and led
to systemic toxicity. Considering the use of naturally occurring substances as carriers, conjugation
can correspond to a more suitable strategy. Nevertheless, none have reached the market yet. With the
gathered information, we hope to assist in the rational planning of strategies to overcome heparin’s
bioavailability and expect this century to be fruitful in rendering an oral active heparin or heparin-like
to reach the market.
Acknowledgments: This work was supported by ERDF, COMPETE, and FCT under the Strategic
Funding UID/Multi/04423/2013, projects PTDC/MAR-BIO/4694/2014 and PTDC/AAG-TEC/0739/2014, and
INNOVMAR—Innovation and Sustainability in the Management and Exploitation of Marine Resources, reference
NORTE-01-0145-FEDER-000035, Research Line NOVELMAR.
Author Contributions: The manuscript was conceived by M.C.S., E.S., and M.P.; A.R.N. and M.C.S. performed
literature review and wrote draft manuscripts. M.P. and E.S. supervised development of the manuscript, and
assisted in data interpretation, manuscript evaluation, and editing.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
The following abbreviations are used in this manuscript:
ATIII Antithrombin III
DMC N,N-Dimethyl chitosan
DMSO Dimethylsulfoxide
DOCA Deoxycholic acid
DOCA-NH2 N-Deoxycholylethylamine
FXa Factor Xa
GA 18β-Glycyrrhetinic acid
GI Gastrointestinal
GSH Glutathione
LMWHs Low molecular weight heparins
MCC Mono-N-carboxymethyl chitosan
PCP-Cys Polycarbophil-cystein
SNAC Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
SNAD Sodium N-[10-(2-hydroxybenzoyl) amino] decanoate
SNOCC N,O-carboxymethyl chitosan
UFH Unfractioned heparin
VKA Vitamin K antagonists
References
1. Wardrop, D.; Keeling, D. The story of the discovery of heparin and warfarin. Br. J. Haematol. 2008, 141,
757–763. [CrossRef] [PubMed]
2. Page, C. Heparin and related drugs: Beyond anticoagulant activity. ISRN Pharmacol. 2013, 2013, 13.
[CrossRef] [PubMed]
3. Lugemwa, F.; Shaikh, K.; Hochstedt, E. Facile and efficient acetylation of primary alcohols and phenols with
acetic anhydride catalyzed by dried sodium bicarbonate. Catalysts 2013, 3, 954–965. [CrossRef]
4. Leone-Bay, A.; Paton, D.R.; Weidner, J.J. The development of delivery agents that facilitate the oral absorption
of macromolecular drugs. Med. Res. Rev. 2000, 20, 169–186. [CrossRef]
5. Weitz, J.I. Low-molecular-weight heparins. N. Engl. J. Med. 1997, 337, 688–699. [PubMed]
6. Hirsh, J.; Levine, M. Low molecular weight heparin. Blood 1992, 79, 1–17. [PubMed]
7. McRae, S.J.; Ginsberg, J.S. Initial treatment of venous thromboembolism. Circulation 2004, 110. [CrossRef]
[PubMed]
8. Jaques, L.B. Heparins-anionic polyelectrolyte drugs. Pharmacol. Rev. 1979, 31, 99–166. [PubMed]
Pharmaceuticals 2016, 9, 37 12 of 16
9. Qi, Y.; Zhao, G.; Liu, D.; Shriver, Z.; Sundaram, M.; Sengupta, S.; Venkataraman, G.; Langer, R.;
Sasisekharan, R. Delivery of therapeutic levels of heparin and low-molecular-weight heparin through
a pulmonary route. Proc. Natl. Acad. Sci. USA 2004, 101, 9867–9872. [CrossRef] [PubMed]
10. Jandik, K.A.; Kruep, D.; Cartier, M.; Linhardt, R.J. Accelerated stability studies of heparin. J. Pharm. Sci. 1996,
85, 45–51. [CrossRef] [PubMed]
11. Ahn, M.Y.; Shin, K.H.; Kim, D.-H.; Jung, E.-A.; Toida, T.; Linhardt, R.J.; Kim, Y.S. Characterization of a
bacteroides species from human intestine that degrades glycosaminoglycans. Can. J. Microbiol. 1998, 44,
423–429. [CrossRef] [PubMed]
12. Kim, D.H.; Kim, B.T.; Park, S.Y.; Kim, N.Y.; Han, M.J.; Shin, K.H.; Kim, W.S.; Kim, Y.S. Degradation of acharan
sulfate and heparin by Bacteroides stercoris HJ-15, a human intestinal bacterium. Arch. Pharmacal Res. 1998,
21, 576–580. [CrossRef]
13. Linker, A.; Hovingh, P. Isolation and characterization of oligosaccharides obtained from heparin by the
action of heparinase. Biochemistry 1972, 11, 563–568. [CrossRef] [PubMed]
14. Bauer, K.A. Pros and cons of new oral anticoagulants. Hematol. Am. Soc. Hematol. Educ. Progr. 2013, 2013,
464–470. [CrossRef] [PubMed]
15. Ludwig, R.J. Therapeutic use of heparin beyond anticoagulation. Curr. Drug Discov. Technol. 2009, 6, 281–289.
[CrossRef] [PubMed]
16. Varki, N.M.; Varki, A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase
of carcinoma metastasis: Rationale for clinical studies in humans. Semin. Thromb. Hemost. 2002, 28, 53–66.
[CrossRef] [PubMed]
17. Wang, L.; Brown, J.R.; Varki, A.; Esko, J.D. Heparin’s anti-inflammatory effects require glucosamine
6-O-sulfation and are mediated by blockade of L- and P-selectins. J. Clin. Investig. 2002, 110, 127–136.
[CrossRef] [PubMed]
18. Arnold, J.; Ahsan, F.; Meezan, E.; Pillion, D.J. Nasal administration of low molecular weight heparin.
J. Pharm. Sci. 2002, 91, 1707–1714. [CrossRef] [PubMed]
19. Yang, T.; Mustafa, F.; Bai, S.; Ahsan, F. Pulmonary delivery of low molecular weight heparins. Pharm. Res.
2004, 21, 2009–2016. [CrossRef] [PubMed]
20. Betz, G.; Nowbakht, P.; Imboden, R.; Imanidis, G. Heparin penetration into and permeation through human
skin from aqueous and liposomal formulations in vitro. Int. J. Pharm. 2001, 228, 147–159. [CrossRef]
21. Gomez-Orellana, I. Strategies to improve oral drug bioavailability. Expert Opin. Drug Deliv. 2005, 2, 419–433.
[CrossRef] [PubMed]
22. Kim, S.K.; Lee, D.Y.; Lee, E.; Lee, Y.-K.; Kim, C.Y.; Moon, H.T.; Byun, Y. Absorption study of deoxycholic
acid-heparin conjugate as a new form of oral anti-coagulant. J. Control. Release 2007, 120, 4–10. [CrossRef]
[PubMed]
23. Park, J.W.; Jeon, O.C.; Kim, S.K.; Al-Hilal, T.A.; Moon, H.T.; Kim, C.Y.; Byun, Y. Anticoagulant efficacy of
solid oral formulations containing a new heparin derivative. Mol. Pharm. 2010, 7, 836–843. [CrossRef]
[PubMed]
24. Eom, J.S.; Koh, K.S.; Al-Hilal, T.A.; Park, J.W.; Jeon, O.C.; Moon, H.T.; Byun, Y. Antithrombotic efficacy of an
oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.
Thromb. Res. 2010, 126, 220–224. [CrossRef] [PubMed]
25. Paliwal, R.; Paliwal, S.R.; Agrawal, G.P.; Vyas, S.P. Biomimetic solid lipid nanoparticles for oral bioavailability
enhancement of low molecular weight heparin and its lipid conjugates: In vitro and in vivo evaluation.
Mol. Pharm. 2011, 8, 1314–1321. [CrossRef] [PubMed]
26. Lee, Y.; Nam, J.H.; Shin, H.C.; Byun, Y. Conjugation of low-molecular-weight heparin and deoxycholic
acid for the development of a new oral anticoagulant agent. Circulation 2001, 104, 3116–3120. [CrossRef]
[PubMed]
27. Lee, Y.-K.; Kim, S.K.; Lee, D.Y.; Lee, S.; Kim, C.-Y.; Shin, H.-C.; Moon, H.T.; Byun, Y. Efficacy of orally
active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
J. Control. Release 2006, 111, 290–298. [CrossRef] [PubMed]
28. Kim, S.K.; Kim, K.; Lee, S.; Park, K.; Park, J.H.; Kwon, I.C.; Choi, K.; Kim, C.-Y.; Byun, Y. Evaluation of
absorption of heparin-doca conjugates on the intestinal wall using a surface plasmon resonance. J. Pharm.
Biomed. Anal. 2005, 39, 861–870. [CrossRef] [PubMed]
Pharmaceuticals 2016, 9, 37 13 of 16
29. Khatun, Z.; Nurunnabi, M.; Cho, K.J.; Lee, Y.-K. Imaging of the GI tract by QDs loaded heparin–deoxycholic
acid (DOCA) nanoparticles. Carbohydr. Polym. 2012, 90, 1461–1468. [CrossRef] [PubMed]
30. Kim, S.K.; Lee, D.Y.; Kim, C.Y.; Nam, J.H.; Moon, H.T.; Byun, Y. A newly developed oral heparin derivative
for deep vein thrombosis: Non-human primate study. J. Control. Release 2007, 123, 155–163. [CrossRef]
[PubMed]
31. Kim, S.K.; Vaishali, B.; Lee, E.; Lee, S.; Lee, Y.-K.; Kumar, T.S.; Moon, H.T.; Byun, Y. Oral delivery of chemical
conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res. 2006, 117, 419–427.
[CrossRef] [PubMed]
32. Lee, Y.-K.; Kim, S.; Byun, Y. Oral delivery of new heparin derivatives in rats. Pharm. Res. 2000, 17, 1259–1264.
[CrossRef] [PubMed]
33. Park, K.; Kim, K.; Kwon, I.C.; Kim, S.K.; Lee, S.; Lee, D.Y.; Byun, Y. Preparation and characterization
of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 2004, 20, 11726–11731.
[CrossRef] [PubMed]
34. Kim, S.K.; Lee, E.H.; Vaishali, B.; Lee, S.; Lee, Y.-K.; Kim, C.-Y.; Moon, H.T.; Byun, Y. Tricaprylin
microemulsion for oral delivery of low molecular weight heparin conjugates. J. Control. Release 2005,
105, 32–42. [CrossRef] [PubMed]
35. Hylemon, P.B.; Zhou, H.; Pandak, W.M.; Ren, S.; Gil, G.; Dent, P. Bile acids as regulatory molecules. J. Lipid Res.
2009, 50, 1509–1520. [CrossRef] [PubMed]
36. Notman, R.; Noro, M.; O’Malley, B.; Anwar, J. Molecular basis for dimethylsulfoxide (DMSO) action on lipid
membranes. J. Am. Chem. Soc. 2006, 128, 13982–13983. [CrossRef] [PubMed]
37. Al-Hilal, T.A.; Park, J.; Alam, F.; Chung, S.W.; Park, J.W.; Kim, K.; Kwon, I.C.; Kim, I.-S.; Kim, S.Y.; Byun, Y.
Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. J. Control. Release 2014, 175,
17–24. [CrossRef] [PubMed]
38. Al-Hilal, T.A.; Chung, S.W.; Alam, F.; Park, J.; Lee, K.E.; Jeon, H.; Kim, K.; Kwon, I.C.; Kim, I.-S.; Kim, S.Y.; et al.
Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci. Rep. 2014,
4, 4163. [CrossRef] [PubMed]
39. Mousa, S.A.; Petersen, L.J. Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence.
Thromb. Haemost. 2009, 102, 258–267. [CrossRef] [PubMed]
40. Lee, D.Y.; Park, K.; Kim, S.K.; Park, R.W.; Kwon, I.C.; Kim, S.Y.; Byun, Y. Antimetastatic effect of an orally
active heparin derivative on experimentally induced metastasis. Clin. Cancer Res. 2008, 14, 2841–2849.
[CrossRef] [PubMed]
41. Lee, D.Y.; Lee, S.W.; Kim, S.K.; Lee, M.; Chang, H.W.; Moon, H.T.; Byun, Y.; Kim, S.Y. Antiangiogenic activity
of orally absorbable heparin derivative in different types of cancer cells. Pharm. Res. 2009, 26, 2667–2676.
[CrossRef] [PubMed]
42. Lee, D.Y.; Kim, S.K.; Kim, Y.S.; Son, D.H.; Nam, J.H.; Kim, I.S.; Park, R.W.; Kim, S.Y.; Byun, Y. Suppression of
angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. J. Control. Release 2007,
118, 310–317. [CrossRef] [PubMed]
43. Khatun, Z.; Nurunnabi, M.; Reeck, G.R.; Cho, K.J.; Lee, Y.-K. Oral delivery of taurocholic acid linked
heparin-docetaxel conjugates for cancer therapy. J. Control. Release 2013, 170, 74–82. [CrossRef] [PubMed]
44. Khatun, Z.; Nurunnabi, M.; Cho, K.J.; Byun, Y.; Bae, Y.H.; Lee, Y.-K. Oral absorption mechanism and
anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. J. Control. Release 2014, 177,
64–73. [CrossRef] [PubMed]
45. Kim, J.-Y.; Al-Hilal, T.A.; Chung, S.W.; Kim, S.Y.; Ryu, G.H.; Son, W.C.; Byun, Y. Antiangiogenic and
anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung
cancer chemoprevention. J. Control. Release 2015, 199, 122–131. [CrossRef] [PubMed]
46. Alam, F.; Al-Hilal, T.A.; Chung, S.W.; Seo, D.; Mahmud, F.; Kim, H.S.; Kim, S.Y.; Byun, Y. Oral delivery
of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using
deoxycholic acid. Biomaterials 2014, 35, 6543–6552. [CrossRef] [PubMed]
47. Tolle-Sander, S.; Lentz, K.A.; Maeda, D.Y.; Coop, A.; Polli, J.E. Increased acyclovir oral bioavailability via a
bile acid conjugate. Mol. Pharm. 2004, 1, 40–48. [CrossRef] [PubMed]
48. Lee, S.; Kim, K.; Kumar, T.S.; Lee, J.; Kim, S.K.; Lee, D.Y.; Lee, Y.-K.; Byun, Y. Synthesis and biological
properties of insulin-deoxycholic acid chemical conjugates. Bioconj. Chem. 2005, 16, 615–620. [CrossRef]
[PubMed]
Pharmaceuticals 2016, 9, 37 14 of 16
49. Reddy, B.S.; Wynder, E.L. Large-bowel carcinogenesis: Fecal constituents of populations with diverse
incidence rates of colon cancer. J. Natl. Cancer Inst. 1973, 50, 1437–1442. [PubMed]
50. Reddy, B.S.; Wynder, E.L. Metabolic epidemiology of colon cancer: Fecal bile acids and neutral sterols in
colon cancer patients and patients with adenomatous polyps. Cancer 1977, 39, 2533–2539. [CrossRef]
51. Ajouz, H.; Mukherji, D.; Shamseddine, A. Secondary bile acids: An underrecognized cause of colon cancer.
World J. Surg. Oncol. 2014, 12, 1–5. [CrossRef] [PubMed]
52. Al-Hilal, T.A.; Alam, F.; Byun, Y. Oral drug delivery systems using chemical conjugates or physical complexes.
Adv. Drug Deliv. Rev. 2013, 65, 845–864. [CrossRef] [PubMed]
53. Park, J.W.; Kim, S.K.; Al-Hilal, T.A.; Jeon, O.C.; Moon, H.T.; Byun, Y. Strategies for oral delivery of
macromolecule drugs. Biotechnol. Bioprocess Eng. 2010, 15, 66–75. [CrossRef]
54. Aungst, B.J. Intestinal permeation enhancers. J. Pharm. Sci. 2000, 89, 429–442. [CrossRef]
55. Motlekar, N.A.; Srivenugopal, K.S.; Wachtel, M.S.; Youan, B.B. Modulation of gastrointestinal permeability
of low-molecular-weight heparin by L-arginine: In vivo and in vitro evaluation. J. Pharm. Pharmacol. 2006,
58, 591–598. [CrossRef] [PubMed]
56. Motlekar, N.A.; Srivenugopal, K.S.; Wachtel, M.S.; Youan, B.B.C. Evaluation of the oral bioavailability of low
molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev. Res. 2006,
67, 166–174. [CrossRef] [PubMed]
57. Imai, T.; Sakai, M.; Ohtake, H.; Azuma, H.; Otagiri, M. In vitro and in vivo evaluation of the enhancing
activity of glycyrrhizin on the intestinal absorption of drugs. Pharm. Res. 1999, 16, 80–86. [CrossRef]
[PubMed]
58. Hisamitsu Pharmaceutical. Products. Available online: http://www.hisamitsu.co.jp/english/products/
(accessed on 24 February 2016).
59. Jiang, L.; Wang, Q.; Shen, S.; Xiao, T.; Li, Y. Discovery of glycyrrhetinic acid as an orally active, direct inhibitor
of blood coagulation factor xa. Thromb. Res. 2014, 133, 501–506. [CrossRef] [PubMed]
60. Bernkop-Schnürch, A.; Greimel, A. Thiomers. Am. J. Drug Deliv. 2005, 3, 141–154. [CrossRef]
61. Thanou, M.; Nihot, M.; Jansen, M.; Verhoef, J.C.; Junginger, H. Mono-N-carboxymethyl chitosan (MCC), a
polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin
across intestinal epithelia in vitro and in vivo. J. Pharm. Sci. 2001, 90, 38–46. [CrossRef]
62. Thanou, M.; Henderson, S.; Kydonieus, A.; Elson, C. N-sulfonato-N,O-carboxymethylchitosan: A novel
polymeric absorption enhancer for the oral delivery of macromolecules. J. Control. Release 2007, 117, 171–178.
[CrossRef] [PubMed]
63. Bueno, P.V.A.; Souza, P.R.; Follmann, H.D.M.; Pereira, A.G.B.; Martins, A.F.; Rubira, A.F.; Muniz, E.C.
N,N-dimethyl chitosan/heparin polyelectrolyte complex vehicle for efficient heparin delivery. Int. J.
Biol. Macromol. 2015, 75, 186–191. [CrossRef] [PubMed]
64. Zhang, H.; Mi, J.; Huo, Y.; Huang, X.; Xing, J.; Yamamoto, A.; Gao, Y. Absorption enhancing effects of
chitosan oligomers on the intestinal absorption of low molecular weight heparin in rats. Int. J. Pharm. 2014,
466, 156–162. [CrossRef] [PubMed]
65. Kast, C.E.; Guggi, D.; Langoth, N.; Bernkop-Schnurch, A. Development and in vivo evaluation of an oral
delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm. Res. 2003, 20,
931–936. [CrossRef] [PubMed]
66. Thanou, M.; Verhoef, J.C.; Nihot, M.T.; Verheijden, J.H.; Junginger, H.E. Enhancement of the intestinal
absorption of low molecular weight heparin (LMWH) in rats and pigs using carbopol 934P. Pharm. Res. 2001,
18, 1638–1641. [CrossRef] [PubMed]
67. Thanou, M.; Verhoef, J.; Junginger, H. Oral drug absorption enhancement by chitosan and its derivatives.
Adv. Drug Deliv. Rev. 2001, 52, 117–126. [CrossRef]
68. Schmitz, T.; Leitner, V.M.; Bernkop-Schnurch, A. Oral heparin delivery: Design and in vivo evaluation of a
stomach-targeted mucoadhesive delivery system. J. Pharm. Sci. 2005, 94, 966–973. [CrossRef] [PubMed]
69. Mori, S.; Matsuura, A.; Rama Prasad, Y.V.; Takada, K. Studies on the intestinal absorption of low molecular
weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats.
Biol. Pharm. Bull. 2004, 27, 418–421. [CrossRef] [PubMed]
70. Rama Prasad, Y.V.; Minamimoto, T.; Yoshikawa, Y.; Shibata, N.; Mori, S.; Matsuura, A.; Takada, K. In situ
intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer.
Int. J. Pharm. 2004, 271, 225–232. [CrossRef] [PubMed]
Pharmaceuticals 2016, 9, 37 15 of 16
71. Ito, Y.; Kusawake, T.; Prasad, Y.V.R.; Sugioka, N.; Shibata, N.; Takada, K. Preparation and evaluation of
oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. Int. J. Pharm. 2006, 317,
114–119. [CrossRef] [PubMed]
72. Malkov, D.; Wang, H.Z.; Dinh, S.; Gomez-Orellana, I. Pathway of oral absorption of heparin with sodium
N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm. Res. 2002, 19, 1180–1184. [CrossRef] [PubMed]
73. Pineo, G.; Hull, R.; Marder, V. Oral delivery of heparin: SNAC and related formulations. Best Pract. Res.
Clin. Haematol. 2004, 17, 153–160. [CrossRef] [PubMed]
74. Berkowitz, S.D.; Marder, V.J.; Kosutic, G.; Baughman, R.A. Oral heparin administration with a novel
drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty.
J. Thromb. Haemost. 2003, 1, 1914–1919. [CrossRef] [PubMed]
75. Salartash, K.; Gonze, M.D.; Leone-Bay, A.; Baughman, R.; Sternbergh, W.C., III; Money, S.R. Oral
low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J. Vasc. Surg.
1999, 30, 526–532. [CrossRef]
76. Emisphere Technologies. Emisphere Technologies Announces Clinical Data on Solid Oral Heparin
Formulations. Available online: http://ir.emisphere.com/releasedetail.cfm?ReleaseID=356222 (accessed on
22 February 2016).
77. Baughman, R.A.; Kapoor, S.C.; Agarwal, R.K.; Kisicki, J.; Catella-Lawson, F.; FitzGerald, G.A. Oral delivery
of anticoagulant doses of heparin: A randomized, double-blind, controlled study in humans. Circulation
1998, 98, 1610–1615. [CrossRef] [PubMed]
78. Mousa, S.A.; Zhang, F.; Aljada, A.; Chaturvedi, S.; Takieddin, M.; Zhang, H.; Chi, L.; Castelli, M.C.;
Friedman, K.; Goldberg, M.M.; et al. Pharmacokinetics and pharmacodynamics of oral heparin solid
dosage form in healthy human subjects. J. Clin. Pharmacol. 2007, 47, 1508–1520. [CrossRef] [PubMed]
79. Emisphere Technologies. Emisphere Technologies Presents First Analysis of Protect Trial at the Annual
Meeting of the American Society of Hematology. Available online: http://ir.emisphere.com/releasedetail.
cfm?ReleaseID=356230 (accessed on 3 April 2016).
80. Hayes, P.Y.; Ross, B.P.; Thomas, B.G.; Toth, I. Polycationic lipophilic-core dendrons as penetration enhancers
for the oral administration of low molecular weight heparin. Biorg. Med. Chem. 2006, 14, 143–152. [CrossRef]
[PubMed]
81. Lee, D.Y.; Lee, J.; Lee, S.; Kim, S.K.; Byun, Y. Lipophilic complexation of heparin based on bile acid for oral
delivery. J. Control. Release 2007, 123, 39–45. [CrossRef] [PubMed]
82. Abdelrahim, A.S.; Ziora, Z.M.; Bergeon, J.A.; Moss, A.R.; Toth, I. Design and synthesis of a series of novel,
cationic liposaccharide derivatives as potential penetration enhancers for oral drug delivery. Tetrahedron
2009, 65, 9436–9442. [CrossRef]
83. Bernkop-Schnürch, A.; Kast, C.; Guggi, D. Permeation enhancing polymers in oral delivery of hydrophilic
macromolecules: Thiomer/GSH systems. J. Control. Release 2003, 93, 95–103. [CrossRef] [PubMed]
84. Hoffart, V.; Lamprecht, A.; Maincent, P.; Lecompte, T.; Vigneron, C.; Ubrich, N. Oral bioavailability of a low
molecular weight heparin using a polymeric delivery system. J. Control. Release 2006, 113, 38–42. [CrossRef]
[PubMed]
85. Hoffart, V.; Ubrich, N.; Lamprecht, A.; Bachelier, K.; Vigneron, C.; Lecompte, T.; Hoffman, M.; Maincent, P.
Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable
and nonbiodegradable polycationic polymers. Drug Deliv. 2003, 10, 1–7. [CrossRef] [PubMed]
86. Hoffart, V.; Ubrich, N.; Simonin, C.; Babak, V.; Vigneron, C.; Hoffman, M.; Lecompte, T.; Maincent, P.
Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release
characteristics. Drug Dev. Ind. Pharm. 2002, 28, 1091–1099. [CrossRef] [PubMed]
87. Jiao, Y.; Ubrich, N.; Hoffart, V.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Maincent, P. Anticoagulant
activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J. Pharm. Sci.
2002, 91, 760–768. [CrossRef] [PubMed]
88. Jiao, Y.; Ubrich, N.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Lecompte, T.; Maincent, P. In vitro and
in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002, 105, 230–235.
[CrossRef] [PubMed]
89. Jiao, Y.Y.; Ubrich, N.; Hoffart, V.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Maincent, P. Preparation
and characterization of heparin-loaded polymeric microparticles. Drug Dev. Ind. Pharm. 2002, 28, 1033–1041.
[CrossRef] [PubMed]
Pharmaceuticals 2016, 9, 37 16 of 16
90. Jiao, Y.Y.; Ubrich, N.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Maincent, P. Preparation and in vitro
evaluation of heparin-loaded polymeric nanoparticles. Drug Deliv. 2001, 8, 135–141. [CrossRef] [PubMed]
91. Kemp, M.M.; Linhardt, R.J. Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
2010, 2, 77–87. [CrossRef] [PubMed]
92. Alf, L.; Petra, K.; Nathalie, U.; Philippe, M.; Dirk, N. Low molecular weight heparin nanoparticles:
Mucoadhesion and behaviour in Caco-2 cells. Nanotechnology 2006, 17, 3673.
93. Lamprecht, A.; Ubrich, N.; Maincent, P. Oral low molecular weight heparin delivery by microparticles from
complex coacervation. Eur. J. Pharm. Biopharm. 2007, 67, 632–638. [CrossRef] [PubMed]
94. Chen, M.C.; Wong, H.S.; Lin, K.J.; Chen, H.L.; Wey, S.P.; Sonaje, K.; Lin, Y.H.; Chu, C.Y.; Sung, H.W.
The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the
oral delivery of heparin. Biomaterials 2009, 30, 6629–6637. [CrossRef] [PubMed]
95. Bagre, A.P.; Jain, K.; Jain, N.K. Alginate coated chitosan core shell nanoparticles for oral delivery of
enoxaparin: In vitro and in vivo assessment. Int. J. Pharm. 2013, 456, 31–40. [CrossRef] [PubMed]
96. Paliwal, R.; Paliwal, S.R.; Agrawal, G.P.; Vyas, S.P. Chitosan nanoconstructs for improved oral delivery of
low molecular weight heparin: In vitro and in vivo evaluation. Int. J. Pharm. 2012, 422, 179–184. [CrossRef]
[PubMed]
97. Saupe, A.; Rades, T. Solid lipid nanoparticles. In Nanocarrier Technologies; Mozafari, M.R., Ed.; Springer:
Dordrecht, The Netherlands, 2006; pp. 41–50.
98. Viehof, A.; Lamprecht, A. Oral delivery of low molecular weight heparin by polyaminomethacrylate
coacervates. Pharm. Res. 2013, 30, 1990–1998. [CrossRef] [PubMed]
99. Goldberg, M.; Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov.
2003, 2, 289–295. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
